{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:45:06Z","timestamp":1790253906637,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.eururo.2011.04.032","type":"journal-article","created":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T17:26:12Z","timestamp":1304270772000},"page":"270-278","source":"Crossref","is-referenced-by-count":57,"title":["The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature"],"prefix":"10.1016","volume":"60","author":[{"given":"Guru","family":"Sonpavde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Malavaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.04.032_bib0005","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2011.04.032_bib0010","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2011.04.032_bib0015","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1470-2045(09)70229-3","article-title":"Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target","volume":"10","author":"Chen","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0020","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ccr.2009.11.006","article-title":"Steroid hormone receptors in prostate cancer: a hard habit to break?","volume":"16","author":"Attard","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2011.04.032_bib0025","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.1158\/0008-5472.CAN-07-2057","article-title":"Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity","volume":"67","author":"Zoubeidi","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0030","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ncpuro1237","article-title":"CYP17 inhibition as a hormonal strategy for prostate cancer","volume":"5","author":"Reid","year":"2008","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0035","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.eururo.2011.04.032_bib0040","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","article-title":"Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0045","doi-asserted-by":"crossref","first-page":"7076","DOI":"10.1074\/jbc.M108255200","article-title":"Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways","volume":"277","author":"Ueda","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.eururo.2011.04.032_bib0050","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1371\/journal.pone.0001006","article-title":"SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas","volume":"2","author":"Compagno","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2011.04.032_bib0055","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.juro.2007.05.129","article-title":"Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy","volume":"178","author":"Morote","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0060","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","article-title":"Prospective identification of tumorigenic prostate cancer stem cells","volume":"65","author":"Collins","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0065","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1073\/pnas.95.9.5246","article-title":"Inactivation of the tumor suppressor PTEN\/MMAC1 in advanced human prostate cancer through loss of expression","volume":"95","author":"Whang","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2011.04.032_bib0070","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","article-title":"Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mce.2008.08.013","article-title":"Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol","volume":"295","author":"Dillard","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0080","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0085","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1158\/0008-5472.CAN-06-3332","article-title":"Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer","volume":"67","author":"Mostaghel","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6601127","article-title":"Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer","volume":"89","author":"Edwards","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2011.04.032_bib0095","first-page":"4315","article-title":"A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy","volume":"61","author":"Gregory","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0100","first-page":"2892","article-title":"Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen","volume":"61","author":"Gregory","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0105","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","article-title":"Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance","volume":"68","author":"Dehm","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0110","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/0008-5472.CAN-08-3605","article-title":"Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy","volume":"69","author":"Steinkamp","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0115","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2003.11.102","article-title":"Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663","volume":"21","author":"Taplin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0120","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(19951015)76:8<1428::AID-CNCR2820760820>3.0.CO;2-T","article-title":"The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer","volume":"76","author":"Small","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.04.032_bib0125","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1200\/JCO.1997.15.8.2928","article-title":"Bicalutamide for advanced prostate cancer: the natural versus treated history of disease","volume":"15","author":"Scher","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0130","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1464-410X.2005.05714.x","article-title":"Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer","volume":"96","author":"Nakabayashi","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.04.032_bib0135","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","article-title":"Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)","volume":"22","author":"Small","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0140","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/annonc\/mdp199","article-title":"Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer","volume":"20","author":"Galsky","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0145","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-06-2344","article-title":"Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study","volume":"13","author":"Ryan","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2011.04.032_bib0150","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1002\/cncr.25194","article-title":"A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer","volume":"116","author":"Shamash","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.04.032_bib0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1530\/acta.0.0900490","article-title":"17 alpha-hydroxylase deficiency. A combination of hydroxylation defect and reversible blockade in aldosterone biosynthesis","volume":"90","author":"Rovner","year":"1979","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.eururo.2011.04.032_bib0160","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1210\/jc.2003-031021","article-title":"Brazilian Congenital Adrenal Hyperplasia Multicenter Study Group. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency","volume":"89","author":"Costa-Santos","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eururo.2011.04.032_bib0165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0960-0760(94)90131-7","article-title":"Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase\/C17-20 lyase)","volume":"50","author":"Barrie","year":"1994","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0170","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1021\/jm981017j","article-title":"The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors","volume":"41","author":"Jarman","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.eururo.2011.04.032_bib0175","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1021\/jm00021a008","article-title":"Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase\/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis","volume":"38","author":"Rowlands","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.eururo.2011.04.032_bib0180","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.bmc.2007.10.094","article-title":"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure","volume":"16","author":"Jagusch","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.eururo.2011.04.032_bib0185","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1021\/jm800355c","article-title":"Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer","volume":"51","author":"Pinto-Bazurco Mendieta","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.eururo.2011.04.032_bib0190","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","volume":"90","author":"O\u2019Donnell","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2011.04.032_bib0195","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0200","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0205","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0210","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","article-title":"Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate","volume":"28","author":"Reid","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0215","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0220","unstructured":"De Bono J, Logothetis CJ, Fizazi K, et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration resistant prostate cancer who have progressed after docetaxel based chemotherapy: results of COU-AA-301, a randomized double blind placebo-controlled phase III study [abstract LBA5]. Abstract presented at: European Society for Medical Oncology Congress; October 8\u201312, 2010; Milan, Italy."},{"key":"10.1016\/j.eururo.2011.04.032_bib0245","doi-asserted-by":"crossref","unstructured":"Scher HI, Logothetis C, Molina A, et al. Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy. Genitourinary Cancers (Symposium abstract 4). Genitourinary Cancer Symposium. Presented February 17, 2011; Orlando, Florida, USA.","DOI":"10.1200\/jco.2011.29.7_suppl.4"},{"key":"10.1016\/j.eururo.2011.04.032_bib0225","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.11733","article-title":"Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study","volume":"98","author":"Van Veldhuizen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2011.04.032_bib0230","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1200\/JCO.2010.29.5170","article-title":"Abiraterone acetate is well tolerated without concomitant use of corticosteroids","volume":"28","author":"Attard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0235","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/S0022-5347(05)66935-2","article-title":"Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer","volume":"164","author":"Palmberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.04.032_bib0240","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811004131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811004131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T12:14:01Z","timestamp":1560168841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811004131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0302283811004131"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.04.032","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}